间充质干细胞来源细胞外囊泡治疗严重肢体缺血的临床前系统评价与荟萃分析
该研究系统评价了间充质干细胞来源细胞外囊泡(MSC-EVs)在严重肢体缺血(CLI)动物模型中的疗效。
要点
- MSC-EVs在CLI动物模型中显著改善灌注恢复,效应量大。
- 脂肪、骨髓和脐带来源MSC-EVs疗效无显著差异。
- 结果支持MSC-EVs作为CLI再生治疗的转化潜力。
核心结论
- MSC-EVs在临床前CLI模型中显著增强灌注恢复,不同MSC来源疗效相当。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA 2020指南并在PROSPERO注册。
- 检索PubMed、ScienceDirect和Europe PMC从建库至2026年3月。
主要发现
- 与对照相比,MSC-EV治疗使灌注恢复显著改善(Hedges' g=4.02,95%CI 3.03-5.01;P<0.00001)。
- 未观察到统计学异质性(I2=0%)。
- 脂肪来源MSC-EVs亚组g=4.46(95%CI 2.81-6.12),骨髓来源g=3.71(95%CI 2.10-5.31),脐带来源g=3.87(95%CI 1.92-5.82),来源间差异无统计学意义(P=0.80)。
临床怎么用
- 为CLI再生治疗提供临床前证据支持,但尚需 rigorously 设计的临床试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Critical limb ischemia (CLI), the most advanced stage of peripheral arterial disease, is associated with substantial risks of limb loss and mortality. As many patients are ineligible for revascularization, novel regenerative therapies are needed. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics due to their pro-angiogenic, anti-inflammatory, and tissue-repair properties. The objective of this study was to systematically evaluate and quantitatively synthesize preclinical evidence regarding the efficacy of MSC-EVs in animal models of CLI or hindlimb ischemia. METHODS: This systematic review and meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 Guidelines and registered in the International Prospective Register of Systematic Reviews. PubMed, ScienceDirect, and Europe PMC were searched from inception to March 2026 for in vivo preclinical studies investigating MSC-EV therapy in CLI or hindlimb ischemia models. Random-effects meta-analysis was performed using Hedges' g. Subgroup analyses were conducted according to MSC source. RESULTS: Thirteen studies met the inclusion criteria for qualitative synthesis, and 7 studies provided sufficient quantitative data and were included in the meta-analysis. Pooled analysis demonstrated a large and significant improvement in perfusion recovery following MSC-EV therapy compared with controls (Hedges' g = 4.02, 95% confidence interval (CI) 3.03-5.01; P<0.00001). No statistical heterogeneity was observed (I2 = 0%). Subgroup analyses showed consistent therapeutic benefits across adipose-derived MSC-EVs (g = 4.46, 95% CI 2.81-6.12), bone marrow-derived MSC-EVs (g = 3.71, 95% CI 2.10-5.31), and umbilical cord-derived MSC-EVs (g = 3.87, 95% CI 1.92-5.82), with no significant differences between sources (P = 0.80). CONCLUSION: MSC-EVs significantly enhance perfusion recovery in preclinical CLI models, with comparable efficacy across different MSC sources. These findings support the translational potential of MSC-EVs as a regenerative therapy for CLI and justify further investigation in rigorously designed clinical trials.
引用
- Guritno T, Wibowo JG, Christophila AB, et al. Therapeutic Efficacy of Mesenchymal Stem Cell-Derived Extracellular Vesicles for Critical Limb Ischemia: A Preclinical Systematic Review and Meta-Analysis with Source-Specific Subgroup Analysis. Ann Vasc Surg. 2026. PMID: 42722062. doi:10.1016/j.avsg.2026.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。